Clinical trials: Stage 3 Acute Kidney Injury
Acute Kidney Injury With Cirrhosis
On Demand Versus Protocol-guided Renal Replacement Therapy for Management of Stage 3 Acute Kidney Injury in Patients With Cirrhosis
Intervention: All patients at presentation would be assessed for the underlying cause of and will be managed by removal of all precipitants(careful review of medications, diuretics, nephrotoxic drugs,vasodilators or non-steroidal…
- Trial name
- NCT02937935
- Testing
- Protocol Guided Renal Replacement Therapy, On Demand Renal Replacement Therapy
- Where
- India
- Volunteers
- 2 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Acute Kidney Injury, Acute Kidney Failure Stage 3
The Performance of Renal Doppler Ultrasound in Predicting Outcome of Dialysis Weaning
Acute kidney injury (AKI) is a frequent problem in the intensive care unit (ICU) affecting more than 50 % of patients. AKI is associated with several adverse outcomes, including increased mortality and increased length of ICU…
- Trial name
- NCT04622384
- Testing
- Dialysis weaning
- Where
- Denmark
- Volunteers
- 33 people
- Sponsor
- Johan Fridolf Hermansen
Empagliflozin in Post AKI Stage 2-3
The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors
Effects of Empagliflozin compared with placebo in post severe acute kidney injury survivors, evaluated by MAKE365.
- Trial name
- NCT05360615
- Testing
- Empagliflozin 10 MG
- Where
- Thailand
- Volunteers
- 147 people
- Sponsor
- Chulalongkorn University
Chronic Kidney Disease, CKD
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the clinical consequences of AKI (MAKE) at 90 days in adult participants with CKD who…
- Conditions
- Chronic Kidney Disease, CKD, Cardiac Disease, Cardiopulmonary Bypass
- Trial name
- ARTEMIS (NCT05746559)
- Testing
- Ravulizumab
- Where
- 130 sites in United States, Argentina and 18 more
- Volunteers
- 555 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Acute Kidney Injury, Chronic Kidney Disease, Stage 3
The Association Between the Duration of Acute Kidney Injury and New-onset Chronic Kidney Disease After Cardiac or Thoracic Aortic Surgery
The investigators aimed to evaluate the association between the duration and stage of acute kidney injury (AKI) and the development of chronic kidney disease during postoperative three years in patients undergoing cardiac or…
- Conditions
- Acute Kidney Injury, Chronic Kidney Disease, Stage 3, Chronic Kidney Disease, Stage 5, Cardiac Surgery
- Trial name
- NCT04172103
- Where
- South Korea
- Volunteers
- 2,009 people
- Sponsor
- Seoul National University Hospital
Chronic Kidney Diseases
A Study to Explore the Renal Safety of Visipaque Injection 320 mgI/mL in Patients With Chronic Kidney Disease
This parallel-group, randomized, placebo-controlled study will examine the incidence and severity of acute kidney injury (AKI) in patients with chronic kidney disease (CKD) stage III/IV following an i.v.
- Trial name
- NCT03119662
- Testing
- Visipaque
- Where
- 29 sites in United States, Belgium and 4 more
- Volunteers
- 4 people
- Sponsor
- GE Healthcare
Acute Kidney Injury
Double-Blind Placebo-Controlled CIN Trial
This double-blinded placebo-controlled study will examine the incidence and significance of contrast-induced acute kidney injury following IV iodine-based contrast material administration in subjects with stage IIIB or stage IV…
- Trial name
- NCT02467075
- Testing
- Iopamidol 300 (Contrast)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Michigan
Acute Kidney Failure Stage 3, Continuous Renal Replacement Therapy (CRRT)
Effect of High Versus Standard Protein Intake in Critically Ill Patients With Acute Kidney Injury Requiring Continuous Renal Replacement Therapy
During critical illness, patients experience a hypercatabolic state. This hypercatabolic state causes muscle wasting in patients, resulting in intensive care unit acquired weakness (ICU-AW).
- Trial name
- PROTEIN-CRRT (NCT07596043)
- Testing
- High protein group, Standard protein group
- Where
- Thailand
- Volunteers
- 56 people
- Sponsor
- Chulalongkorn University
Acute Kidney Injury, Stage 2 Acute Kidney Injury
VIDAS® NEPHROCLEAR Diagnostic Accuracy Study
This is a multi-center sample analysis study in which urine samples previously collected from persons with Stage 2 or Stage 3 Acute Kidney Injury (AKI), will be tested in order to validate the VIDAS® NEPHROCLEAR™ CCL14 Test
- Conditions
- Acute Kidney Injury, Stage 2 Acute Kidney Injury, Stage 3 Acute Kidney Injury
- Trial name
- NCT06036758
- Testing
- VIDAS® NEPHROCLEAR™ CCL14 Test
- Where
- 2 sites in United States
- Volunteers
- 477 people
- Sponsor
- BioMérieux
Acute Kidney Injury Due to Sepsis
(Revival) Study to Investigate the Efficacy and Safety of Alkaline Phosphatase in Patients With Sepsis-Associated AKI
Clinical phase 3 study to investigate the effect of recAP on 28 day mortality in patients admitted to the ICU with acute kidney injury that is caused by sepsis. The study has three distinct SA-AKI trial populations: 1.
- Trial name
- NCT04411472
- Testing
- Recombinant human alkaline phosphatase
- Where
- 122 sites in United States, Australia and 13 more
- Volunteers
- 676 people
- Sponsor
- AM-Pharma
Acute Kidney Injury, Peritonitis
Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury
Phase 3 multicenter study to be conducted in up to 90 qualified participating sites globally to assess the efficacy and safety of Reltecimod vs placebo in patients with sepsis-associated Stage 2/3 AKI.
- Conditions
- Acute Kidney Injury, Peritonitis, Necrotizing Soft Tissue Infection
- Trial name
- NCT03403751
- Testing
- Reltecimod 0.5 mg/kg
- Where
- 56 sites in United States, France
- Volunteers
- 58 people
- Sponsor
- Atox Bio Ltd
Multiple Myeloma and Plasma Cell Neoplasm, Renal Failure
Dexamethasone and Chemotherapy With or Without Plasma Exchange in Patients With Newly Diagnosed Multiple Myeloma and Acute Kidney Failure
RATIONALE: Dexamethasone is used to treat multiple myeloma. Drugs used in chemotherapy may stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00416897
- Testing
- chemotherapy, dexamethasone, plasmapheresis
- Where
- 39 sites in United Kingdom
- Volunteers
- 280 people
- Sponsor
- University of Glasgow
Chronic Kidney Disease stage3, Contrast-induced Nephropathy
Renoprotective Effect of Febuxostat on Contrast Induced Acute Kidney Injury in Chronic Kidney Disease Patients Stage 3
This study will determine the renoprotective effect of febuxostat in prevention of contrast induced acute kidney injury in chronic kidney disease patients Stage 3 undergoing percutaneous coronary intervention.
- Trial name
- NCT05264584
- Testing
- Isotonic saline, N-acetyl cysteine, Febuxostat 80 MG
- Where
- Egypt
- Volunteers
- 120 people
- Sponsor
- Ain Shams University
Delayed Graft Function
Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney
The major objective is to demonstrate the safety and efficacy of ANG-3777 in improving graft function and reducing the severity of delayed graft function (DGF) in recipients at high risk of DGF after receiving a deceased donor…
- Trial name
- NCT02474667
- Testing
- ANG-3777
- Where
- 30 sites in United States
- Volunteers
- 253 people
- Sponsor
- Angion Biomedica Corp
Acute Kidney Failure Stage 3
Venous Excess and Lung Ultrasound During Continuous Kidney Replacement Therapy in Critically Ill Patients
Hemodynamic management of critically ill patients has long been focused on the arterial side of the vasculature by assessing adequate perfusion pressure. However, the venous pressure is also of critical importance.
- Trial name
- VExLUS-KRT (NCT06254703)
- Testing
- VExUS (venous excess ultrasound), modified VExUS (modified venous excess ultrasound)
- Where
- Thailand
- Volunteers
- 100 people
- Sponsor
- Chulalongkorn University
Thrombotic Microangiopathy
Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger
This study will investigate the efficacy and safety of ravulizumab compared to placebo in adult participants with thrombotic microangiopathy (TMA) associated with a trigger.
- Trial name
- NCT04743804
- Testing
- Ravulizumab, Best Supportive Care
- Where
- 97 sites in United States, Belgium and 11 more
- Volunteers
- 16 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
COVID-19
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia
A new drug called azeliragon could be used to treat patients with COVID-19 or other pneumonia infections but the researchers don't know.
- Trial name
- NCT05815485
- Testing
- Azeliragon
- Where
- 3 sites in United States
- Volunteers
- 144 people
- Sponsor
- The University of Texas Medical Branch, Galveston
Chronic Kidney Disease Stage 4, Chronic Kidney Disease Stage 3B
Fluorescein Angiography in Patients With Diabetes and Chronic Kidney Disease
Our study hypothesizes that fluorescein exposure in diabetic patients with advanced chronic kidney disease results in deterioration of kidney function.
- Conditions
- Chronic Kidney Disease Stage 4, Chronic Kidney Disease Stage 3B, Chronic Kidney Disease Stage 5, Diabetes Mellitus
- Trial name
- Fluo-AKI (NCT06760650)
- Testing
- Fluorescein angiography
- Where
- Lebanon
- Volunteers
- 35 people
- Sponsor
- Saint-Joseph University
Cardiac Surgery
QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery
This trial is designed to evaluate QPI-1002 versus placebo for the prevention of Major Adverse Kidney Events (MAKE) in subjects at high risk for acute kidney injury following cardiac surgery.
- Trial name
- NCT03510897
- Testing
- teprasiran
- Where
- 104 sites in United States, Australia and 9 more
- Volunteers
- 1,043 people
- Sponsor
- Quark Pharmaceuticals
Acute Kidney Injury
Nafamostat Efficacy in Phase 3 Registrational CRRT Study
A prospective, randomized, placebo-controlled clinical study to investigate the safety and efficacy of Niyad (nafamostat mesylate) for anticoagulation of extracorporeal blood circulating through a dialysis filter in patients…
- Trial name
- NEPHRO (NCT06150742)
- Testing
- Niyad (nafamostat mesylate)
- Where
- 10 sites in United States
- Volunteers
- 70 people
- Sponsor
- Talphera, Inc